Clinical Report: Mild metabolic profile may mask MASLD risk

Overview

This study identifies five distinct subgroups of metabolic dysfunction-associated steatotic liver disease (MASLD) with varying genetic profiles and disease trajectories. Notably, a polygenic subgroup with mild metabolic abnormalities presents significant long-term liver risks.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern, particularly due to its complex interplay of genetic, metabolic, and environmental factors. Understanding the heterogeneity of MASLD is crucial for effective risk stratification and management, as it encompasses a spectrum from simple steatosis to severe liver disease.

Data Highlights

Key Findings

• Five reproducible subgroups of MASLD were identified based on clinical and demographic variables.
• The polygenic MASLD subgroup (C4) exhibited mild metabolic abnormalities but significant liver-specific risks.
• Patients in C5 had more than double the likelihood of developing metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis compared to C1.
• Long-term liver transplantation likelihood was 16% in C4 and 10% in C5 over 10 years.
• Subgroups C2 and C3 showed heterogeneous metabolic profiles, while C4 and C5 were more liver-focused.

Clinical Implications

The identification of distinct MASLD subgroups emphasizes the importance of understanding genetic and metabolic risk profiles.

Conclusion

This study highlights the complexity of MASLD and the need for further research to refine subgroup assignments and validate findings across diverse populations.

Related Resources & Content

1. Priya TS, et al., Nature Communications, 2026 -- Subtyping metabolic dysfunction-associated steatotic liver disease using electronic health record-linked genomic cohorts reveals diverse etiologies and progression
2. Journal of Gastroenterology and Hepatology, 2026 -- Smoking and Risk of Hepatic Steatosis Within the MASLD Spectrum in Korean Young Adults
3. Frontiers in Medicine, 2026 -- Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study
4. Archives of Toxicology, 2024 -- Alterations in the Antioxidant System Induced by Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review
5. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - PMC, 2024
6. Influence of Heart Function on the Assessment of MASLD Using Indocyanine Green Clearance
7. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - PMC
8. Subtyping metabolic dysfunction-associated steatotic liver disease using electronic health record-linked genomic cohorts reveals diverse etiologies and progression | Nature Communications